928672-86-0 Usage
Description
Canagliflozin, an orally active and selective sodium–glucose
cotransporter 2 (SGLT2) inhibitor, was co-developed by
Mitsubishi Tanabe Pharma and Johnson & Johnson (J&J) for the
treatment of type 2 diabetes mellitus (T2DM) and obesity. The
drug was approved in March by the U.S. FDA and launched in
April 2013 in the U.S. SGLT2 is involved in the glucose re-absorption
pathway in the kidney, and its inhibition increases urinary
glucose excretion, and reduces plasma glucose and HbA1c levels.
In addition, canagliflozin is safe in combination with other commonly
used antidiabetic agents and has a significant effect on body
weight reduction. A recently published process patent from
ScinoPharm Taiwan describes the synthesis of canagliflozin.
Uses
Canagliflozin Hemihydrate is a derivative of Canagliflozin (C175190), which is a sodium/glucose cotransporter 2 (SGLT2) inhibitor. Canagliflozin has been shown to dose dependently reduce calculated renal threshold for glucose excretion and increase urinary glucose excretion. Canagliflozin is a candidate for the treatment of type 2 diabetes and obesity.
Synthesis
Synthesis of the aglycone region of canagliflozin was described
in a separate patent by first condensing commercially available 5-
bromo-2-methylbenzoyl chloride (14) and 2-(4-fluorophenyl)-
thiophene (15) under Friedel–Crafts acylation conditions to give
ketone 16 in 69% yield as a crystalline solid. Ketone 16 was then
reduced with triethylsilyl hydride in the presence of BF3Et2O at
low temperature to give aglycone bromide 17 in 70% yield. The
precursor for the glycoside moiety, commercially available glycoside
triol 18, was selectively treated with t-butyldiphenylsilyl
chloride (TBDPSCl) in THF in the presence of imidazole to give
the bis-silyl ether 19 in 81% yield. Next, a unique, stereospecific
b-C-arylglucosidation was developed to secure the union of the
aglyone- and glycoside-containing portions of canagliflozin.
Bromide 17 was subjected to magnesium powder under standard
Grignard conditions prior to treatment with AlCl3 in THF in situ.
This resulting mixture was then exposed to a solution of compound
19 in PhOMe which had been pre-treated with n-BuLi, and the entire mixture was then warmed to 150 ℃ for 5 h to ultimately
give the b-anomer 20 in 56% yield. Finally, removal of the silyl
groups within 20 with tetrabutyl ammonium fluoride (TBAF) in
THF delivered canagliflozin hydrate (III) in 73% yield.
Check Digit Verification of cas no
The CAS Registry Mumber 928672-86-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,2,8,6,7 and 2 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 928672-86:
(8*9)+(7*2)+(6*8)+(5*6)+(4*7)+(3*2)+(2*8)+(1*6)=220
220 % 10 = 0
So 928672-86-0 is a valid CAS Registry Number.
928672-86-0Relevant articles and documents
NOVEL CRYSTALLINE HYDRATES OF 1-(?-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE
-
Page/Page column 21; 22, (2014/12/09)
The present invention relates to non-stoichiometric crystalline hydrates of 1-(?-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene, processes for their preparation, and their use as medicaments. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel crystalline hydrates.
